JAMA Publishes Geneoscopy’s Pivotal CRC-PREVENT Trial Results, Reporting Highest Sensitivity for Detecting Colorectal Cancer and Advanced Adenomas Among Available Noninvasive Screening Tests
Geneoscopy’s noninvasive, multi-target, stool RNA (mt-sRNA) colorectal cancer screening test showed extraordinary sensitivity for detecting…
Geneoscopy to Present and Exhibit at American College of Gastroenterology 2023 Annual Meeting
Company to Showcase Its Noninvasive RNA-based Technology Platform Designed to Improve Diagnostic Tools for Gastrointestinal Health ST LOUIS, MO –…
Geneoscopy appoints Don Hardison to its Board of Directors
ST. LOUIS, Feb. 28, 2023 /PRNewswire/ Geneoscopy, a developer of innovative diagnostics for gastrointestinal health, announced the appointment of…
Geneoscopy Submits Premarket Approval Application to FDA for its Noninvasive Colorectal Cancer RNA Biomarker Screening Test
FDA’s Decision Forthcoming for Innovative Test with Agency’s Breakthrough Device Designation ST LOUIS, Jan. 24, 2023 / — Geneoscopy, Inc., a…
Geneoscopy’s Noninvasive Colorectal Cancer Screening Test Demonstrates High Sensitivity and Specificity in Large Pivotal Clinical Trial
Colorectal Cancer and Advanced Adenoma Sensitivity Results are the Highest Reported from any Prospective Pivotal Study for a Noninvasive Screening…
Geneoscopy announces rebranding
New look matches focus on transforming GI health ST. LOUIS, MISSOURI (October 3, 2022) | Geneoscopy today announced a corporate rebrand…
Geneoscopy Completes Pivotal Colorectal Cancer Trial Enrollment with Diverse Participant Population
Trial Enrollment Over Indexes in Traditionally Under-Represented Black Community ST. LOUIS, Aug. 23, 2022 /PRNewswire/ -- Geneoscopy Inc., a life…